ArticleCell2024
RNA aggregates harness the danger response for potent cancer immunotherapy.
Abstract read
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed.
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Review
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.Medical sciences (Basel, Switzerland) · 2026Review
- Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026Review
- Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026Review
- A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.Cancer immunology, immunotherapy : CII · 2026Article
- Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.Nature cancer · 2026Article
- Programming the immunological properties of mRNA vaccines for cancer.Nature reviews. Immunology · 2026Review
- A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads.Advanced healthcare materials · 2026Article
- Glioblastoma Stem Cells as Targets for Emerging Precision Immunotherapies and Molecular Treatments.Cells · 2026Review
- Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy.The Journal of clinical investigation · 2026Article
- Deciphering the tumor microenvironment and role of immunotherapy in diffuse midline glioma: A scoping review.Neuro-oncology · 2026Article
- Cat viruses as windows into human oncogenesis.Nature reviews. Cancer · 2026Article
- Imaging assessment of immunotherapy in pediatric brain tumors.Journal of neuro-oncology · 2026Review
- AI-driven computational methods and benchmarking for T-cell antigen identification.Briefings in bioinformatics · 2026Review
- Article
- mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.MedScience · 2026Review
- Intranasal circRNA vaccine elicits localized and safer antitumor immunity.Journal of the National Cancer Center · 2026Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
57 authors.
Hector R Mendez-GomezUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Anna DeVriesUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Paul CastilloUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Christina von RoemelingUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Sadeem QdaisatUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA; University of Florida Genetics Institute, Gainesville, FL 32610, USA.
Brian D StoverUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Chao XieUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Frances WeidertUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Chong ZhaoUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Rachel MoorUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Ruixuan LiuUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Dhruvkumar SoniUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Elizabeth Ogando-RivasUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Jonathan Chardon-RoblesUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
James McGuinessUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Dingpeng ZhangUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Michael C ChungUniversity of Texas at Austin, College of Pharmacy, Division of Chemical Biology and Medicinal Chemistry, Austin TX 78712.
Christiano MarconiUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Stephen MichelUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Arnav BarpujariUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Gabriel W JobinUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Nagheme ThomasUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Xiaojie MaUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA; University of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Yodarlynis CampaneriaUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Adam GrippinUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Aida KarachiUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Derek LiUniversity of Florida, Division of Quantitative Sciences, UF Health Cancer Center, Gainesville, FL 32610, USA.
Bikash SahayUniversity of Florida, College of Veterinary Medicine, Gainesville, FL 32610, USA.
Leighton ElliottUniversity of Florida, Department of Medicine, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Timothy P FosterUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Kirsten E ColemanUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Rowan J MilnerUniversity of Florida, College of Veterinary Medicine, Gainesville, FL 32610, USA.
W Gregory SawyerH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
John A LigonUniversity of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA.
Eugenio SimonUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Brian CleaverUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Kristine WynneUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Marcia HodikUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Annette M MolinaroUniversity of California, San Francisco, Department of Neurological Surgery, San Francisco, CA 94158, USA.
Juan GuanUniversity of Texas at Austin, College of Pharmacy, Division of Chemical Biology and Medicinal Chemistry, Austin TX 78712.
Patrick KellishUniversity of Florida Interdisciplinary Center for Biotechnology Research, Gainesville, FL 32610, USA.
Andria DotyUniversity of Florida Interdisciplinary Center for Biotechnology Research, Gainesville, FL 32610, USA.
Ji-Hyun LeeUniversity of Florida, Department of Biostatistics, Gainesville, FL 32610, USA.
Tara MassiniUniversity of Florida, Department of Radiology, Gainesville, FL 32610, USA.
Jesse L KresakUniversity of Florida, Department of Pathology, Gainesville, FL 32610, USA.
Jianping HuangUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Eugene I HwangChildren's National Hospital, Center for Cancer and Blood Disorders, Washington, DC 20010, USA.
Cassie KlineUniversity of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Department of Pediatrics, Division of Oncology, Philadelphia, PA 19104, USA.
Sheila Carrera-JustizUniversity of Florida, College of Veterinary Medicine, Gainesville, FL 32610, USA.
Maryam RahmanUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Sebastian GaticaUniversity of Florida, Department of Anesthesiology, Gainesville, FL 32610, USA.
Sabine MuellerUniversity of California, San Francisco, Department of Neurology, Neurological Surgery, and Pediatrics, San Francisco, CA 94158, USA.
Michael PradosUniversity of California, San Francisco, Department of Neurological Surgery, San Francisco, CA 94158, USA.
Ashley P GhiaseddinUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Natalie L SilverCleveland Clinic, Center of Immunotherapy and Precision Immuno-Oncology/Head and Neck Institute, Cleveland, OH 44106, USA.
Duane A MitchellUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA.
Elias J SayourUniversity of Florida Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, FL 32610, USA; University of Florida, Department of Pediatrics, Division of Hematology-Oncology, Gainesville, FL 32610, USA. Electronic address: elias.sayour@neurosurgery.ufl.edu.
Funding
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026
$16.0MOvercoming the blood-brain barrier with nanoparticle vaccines against gliomasR37CA251978 · NCI · UNIVERSITY OF FLORIDA · PI Elias Sayour · 2021 to 2026
$3.4MInterdisciplinary Translational Pre/Postdoctoral Program in Cancer NanotechnologyT32CA196561 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Gang Bao, Konstantin V Sokolov · 2015 to 2026
$3.0MOvercoming metastatic spread of osteosarcoma with RNA loaded nanoparticlesR01CA266857 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2022 to 2025
$2.9MMechanisms of Assembly and Functional Regulation in Non-canonical Biomolecular CondensatesR35GM146877 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Juan Guan · 2022 to 2026
$2.0MHarnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting GlioblastomaK08CA199224 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2016 to 2020
$791kRemodeling host immunity in oral cancer with personalized RNA nanoparticle vaccinesK08DE029503 · NIDCR · UNIVERSITY OF FLORIDA · PI SILVER, NATALIE LEA · 2020 to 2024
$777kNikon A1R two-photon microscope for a shared resourceS10OD020026 · OD · UNIVERSITY OF FLORIDA · PI KHOSHBOUEI, HABIBEH · 2015 to 2015
$600kFDA HHS R01 FD007268NCI NIH HHS K08 CA199224NCI NIH HHS R01 CA266857NCI NIH HHS R37 CA251978NCI NIH HHS T32 CA196561NIDCR NIH HHS K08 DE029503NIDDK NIH HHS K12 DK133995NIGMS NIH HHS R35 GM146877NIH HHS S10 OD020026
Abstract
Cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Here, we create "onion-like" multi-lamellar RNA lipid particle aggregates (LPAs) to substantially enhance the payload packaging and immunogenicity of tumor mRNA antigens. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for Toll-like receptor engagement in immune cells, systemically administered RNA-LPAs activate RIG-I in stromal cells, eliciting massive cytokine/chemokine response and dendritic cell/lymphocyte trafficking that provokes cancer immunogenicity and mediates rejection of both early- and late-stage murine tumor models. In client-owned canines with terminal gliomas, RNA-LPAs improved survivorship and reprogrammed the TME, which became "hot" within days of a single infusion. In a first-in-human trial, RNA-LPAs elicited rapid cytokine/chemokine release, immune activation/trafficking, tissue-confirmed pseudoprogression, and glioma-specific immune responses in glioblastoma patients. These data support RNA-LPAs as a new technology that simultaneously reprograms the TME while eliciting rapid and enduring cancer immunotherapy.
Indexed as
ImmunotherapyLipidsRNATumor MicroenvironmentAnimalsAntigens, NeoplasmBrain NeoplasmsCancer VaccinesCell Line, TumorCytokinesDendritic CellsDogsFemaleGlioblastomaGliomaHumansAntigens, NeoplasmCancer VaccinesCytokinesLipidsRNARNA, Messengerbrain tumorscancer immunotherapycancer vaccinesglioblastomalipid nanoparticlesmRNApersonalized therapytranslational therapeutics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.